The ontogeny of 3,4-dihydroxyphenylacetic acid in human cerebrospinal fluid

G. M. Anderson, M. A. Riddle, E. L. Hoder, F. C. Feibel, B. A. Shaywitz, D. J. Cohen

Research output: Contribution to journalArticle

Abstract

Measurement of cerebrospinal fluid (CSF) levels of the minor dopamine metabolite 3,4-dihydroxyphenylacetic acid in neonates and children indicates that a rapid decline (approximately 90%) occurs in the first 2 years of life. The much less rapid ontogenetic decline seen for the predominant dopamine metabolite, homovanillic acid (HVA), indicates that differing factors affect CSF levels of the two acid metabolites. Further study is required to determine which compound more closely reflects ontogenetic changes in dopamine functioning.

Original languageEnglish (US)
Pages (from-to)1100-1102
Number of pages3
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume51
Issue number8
DOIs
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'The ontogeny of 3,4-dihydroxyphenylacetic acid in human cerebrospinal fluid'. Together they form a unique fingerprint.

  • Cite this